CTOs on the Move

Human Genome Sciences

www.hgsi.com

 
Human Genome Sciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.hgsi.com
  • 14200 Shady Grove Rd
    Rockville, MD USA 20850
  • Phone: 301.309.8504

Executives

Name Title Contact Details

Similar Companies

Ethicon Endo-Surgery

Ethicon Endo-Surgery is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accent Therapeutics

Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.

Nemus Bioscience

Nemus Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. NEMUS Bioscience Inc. is developing a novel and proprietary class of product candidates that are designed to target the body`s nervous and immune systems without inducing many of the undesirable side effects typically associated with currently available therapeutics. NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS. To become a leading developer of cannabis-based therapeutics to address unmet medical needs on a global basis.

ProThera Biologics (Main)

ProThera Biologics, LLC (Main) is a East Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.